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Abstract: 
 
Introduction:  During the last decade, the results of several clinical studies suggested 
that oral probiotics may potentially improve oral health.  The first study examining the 
effects of probiotics on oral health demonstrated that almost every patient with gingivitis, 
periodontitis or pregnancy gingivitis, had significant improvements in measurable 
periodontal indices when they were treated with a locally administered culture 
supernatant of a Lactobacillus acidophilus strain. This finding sparked several other 
studies to further examine the potential for treating oral diseases, such as, combating 
halitosis, oral candidiasis, and dental caries with probiotics.  Of our interest, Fernandez et 
al.  and Hollstrom et al. published their clinical studies investigating the effects of 
probiotics on peri-implant mucositis lesions and had conflicting results.  In a recent study 
investigating the effect of Lactobacillus reuteri on peri-implantitis lesions, it was 
concluded that the oral probiotics together with mechanical debridement gave additional 
improvement for all clinical parameters.  However, more studies are needed to confirm 
this finding as the majority of published studies explored the effects of probiotics on  
vi 
   
periodontitis and peri-implant mucositis lesions, very few focused specifically on peri-
implantitis lesions.  Therefore, the goals of this study were to examine the clinical, 
inflammatory and microbiological effects of oral probiotics when used as an adjunct in 
addition to non-surgical debridement in treating peri-implantitis lesions.  Methods: A 
double blind pilot study was conducted between the test group (probiotics) versus the 
control group  (placebo) as an adjunct to non-surgical treatment of peri-implantitis sites.  
Peri-implantitis is defined when there is a probing depth of 6mm or more with bleeding 
on probing and 3mm or more radiographic bone loss compared to radiographs when 
implants were placed.  A full mouth non-surgical treatment was performed and peri-
implantitis sites were debrided using titanium curettes.  Subsequently, oral probiotics 
containing strains of S. salivarius K12, S. salivarius M18, L. reuteri and L. paracasei 
were given to the test group while the control group received placebo tablets.  
Subgingival plaque, gingival crevicular fluid/peri-implant crevicular fluid volume and 
clinical parameters such as probing depth,clinical attachment level, bleeding on probing 
plaque index and gingival index were recorded for analysis.  Moreover, these data were 
collected from not only peri-implantitis sites of each subject but also from healthy and 
periodontitis sites of all patients. Microbiological testing was done by 16sRNA analysis 
and GCF/PICF analysis were done by ELISA. Statistical analyses were done by using 
One-way Anova.  Results: There were no statistically significant differences for all 
clinical parameters comparing baseline to 90 days for the test and control groups at all 
sites.  However, biologically, only probiotic group in peri-implantitis sites demonstrated 
statistically significant reduction after 90 days. Moreover, there were no statistical 
differences for MMP-9 or interleukin-1β. There was a statistically significance increase 
for P. gingivalis for peri-implantitis sites (p=0.04) for the probiotic group. There was  
vii 
   
statistically significant increase in commensal bacteria of the green, purple and blue 
complexes specifically C.concisus (p=0.028), A. graevenitzii (p=0.023) and Actinomyces 
species (p=0.015) in probiotic group in peri-implantitis sites compared to placebo. .  
Conclusions:  Our findings suggest that adjunctive use of oral probiotics appeared to 
have limited effects on clinical parameters, however, biologically, they significantly 
decreased PICF TNF-α levels, a pro-inflammatory cytokine which is associated with 
periodontal and peri-implant breakdown.  Furthermore, oral probiotics may help to shift 
the microbial flora towards commensal bacteria as it was shown to be statistically 
increased. in peri-implantitis sites.  This suggests that oral probiotics may play a role in 
affecting the overall microbiota of the oral cavity shift towards a healthier and more 
symbiotic environment.   
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1.1.1. History of Probiotics 
 
Probiotics, derived from the Greek word bio-tikos “for life”, has been a subject of 
interest in modern health care. In 1907, Metchnikoff, a Nobel Prize winner, was 
the first to discover the positive role of selected bacteria.1 He advocated that “the 
dependence of intestinal microbes on food makes it possible to adopt measures to 
modify the flora in our bodies and to replace the harmful microbes by useful 
microbes”.1 Around the same time, Tissier, a French pediatrician, recognized that 
children with diarrhea had minimal numbers of “bifid” bacteria compared to 
healthy children.2  He proposed that these bacteria could restore a healthy gut 
flora in patients with diarrhea.2 Even though Metchnikoff & Tissier were amongst 
the first to explore the probiotic usage of bacteria, the term “probiotic” was not 
coined until 1960 to describe the substance produced by microorganisms that 
promote growth of other microorganisms.3 In 2001, the Food & Agriculture 
Organization of the United Nations-World Health Organization (FAO-WHO) 
officially defined probiotics as “live microorganisms that when administered in 
adequate amounts confer a significant health benefit on the host”.4 This definition 
was later adopted by the International Scientific Association for Probiotics and 
Prebiotics (ISAPP) and remained to date to be the most accepted definition of 
probiotics worldwide. 
 
1.1.2 Probiotics and Oral Health: 
During the last decade, several authors speculated that probiotic bacteria, used 




suggested that benefits include combating halitosis, oral candidiasis, and dental 
caries.6   In addition, the first studies to use probiotics for oral health were targeted 
to treat periodontal inflammation.7 Significant improvement in measurable 
periodontal indices was observed for almost every patient when patients with 
various periodontal diseases such as gingivitis, periodontitis and pregnancy 
gingivitis were locally treated with a culture supernatant of a Lactobacillus 
acidophilus strain.7 This sparked several other studies that further examined  the 
potential of probiotics for treating periodontal diseases.  The strains used in these 
studies include Lactobacilus reuteri, Lactobacillus brevis (CD2), Lactobacillus 
casei Shirota, Lactobacillus salivarius WB21 and Bacillus subtilis spp.  There was 
a decrease in gingival bleeding with the use of L. reuterui and L brevis.8-10 
Specifically, L. reuteri in chewing gum was shown to decrease the levels of pro-
inflammatory cytokines in gingival crevicular fluid (GCF) while L. brevis 
decreased inflammatory markers in saliva, including MMP (collagenase) 
activity.9,10 L. casei Shirota decreased gingival inflammation, PMN elastase, and 
MMP-3 activities in GCF after 4-days and B. subtilis reduced the number of 
periodontal pathogens.11,12  Gingival pocket depths and sum of periodontal 
pathogens in plaque decreased with L. salivarius WB21, especially in 
smokers.13,14  
With the growing interest in using probiotics in periodontal therapy, newly 
emerging research assessed the effects of probiotics on oral health.  Kuru et al. 
(2017) assessed the effect of yogurt supplemented with Bifidobacterium animalis 




They concluded in this single-blinded randomized controlled study that the use of 
a probiotic yogurt supplemented with B. animalis appeared to have a positive 
effect on plaque accumulation and gingival parameters after the oral hygiene 
regimen was stopped.15 Moreover, Shah et al. (2017) recognized the concerns 
regarding the overuse and broad use of antibiotics.  As a result, the authors 
conducted a randomized controlled trial using L. brevis CD2 lozenges, L. brevis 
CD2 with oral doxycycline, or doxycycline alone to assess their effects on 
patients with aggressive periodontitis.  After 14 days of treatment, they found that 
lozenges containing L. brevis CD2 had a lasting and positive effect on clinical 
measures of aggressive periodontitis, especially the gingival index.  In addition, 
they found the effects of L. brevis CD2 to be equivalent to those of doxycycline.16 
 
1.1.3. Why Probiotics?   
Globally, we have seen that increasing and often inappropriately 
widespread use of antibiotics has, correspondingly, increased the antibiotic-
resistance of bacteria in all major human organ systems, including the subgingival 
microbiota of adult periodontitis patients.15 According to the Centers for Disease 
Control and Prevention, “at least 2 million people in the US become infected with 
bacteria that are resistant to antibiotics and at least 23,000 people die each year as 
a direct result of these infections.16 Thus, it is important to seek alternative anti-
microbial approaches such as the exploring the potential of health-promoting 
bacteria for therapeutic purposes.  The concept itself is straightforward. 
Antibiotics not only destroy the harmful bacteria but can also suppress the 




repopulate the beneficial bacteria to strengthen the fight against infection. 
Probiotics are already often recommended to patients with a history of diarrhea or 
overall gastrointestinal irritation, while, at the same time, taking antibiotics to 
minimize symptoms.   
 
1.1.4. Probiotics: Proposed Mechanisms 
Numerous major mechanisms have been proposed to explain the bio-
protective role of probiotics. For instance, oral health may benefit from probiotics 
by preventing the growth of harmful microbiota or by modifying immunity in the 
oral cavity.15  Haukiojia et al. (2006) demonstrated that certain strains of 
probiotics remove a crucial adhesion protein, salivary agglutinin gp340, which is 
necessary for the adhesion of S. mutans , thus decreasing the colonizing efficiency 
of S. mutans. In addition, the competitive exclusion mechanism of probiotics may 
hinder adhesion of pathogenic bacteria or compete for the same nutrients and 
thus, shift the species to another niche or lead to extinction of the weaker 
competitor.17 Probiotics may possibly compete for certain essential nutrients or 
chemicals necessary for the growth of pathogens and block them out, thus, 
improving oral health.  Moreover, probiotics can produce a diverse range of 
antimicrobial substances such as lactic acid, hydrogen peroxide, bacteriocins and 
bacteriocin-like inhibitory substances.18 Sookkhee et al. (2001) isolated lactic acid 
bacteria from healthy oral cavities and demonstrated their antimicrobial effect 
against Porphyromonas gingivalis and Streptococcus mutans.19 Koll-Klais et al. 




homofermentative Lactobacilli, especially Lactobacillus gasseri in healthy 
individuals versus individuals with periodontitis.20  Since higher concentrations of 
lactic acid was produced by homofermentative Lactobacilli in comparison with 
heterofermentative lactobacilli, P. gingivalis and Prevotella intermedia were 
significantly inhibited.20   
Probiotics can also indirectly exert their actions in the oral cavity by 
modulating the body’s immune function.21  Host cells such as epithelial cells and 
immune cells can recognize probiotic bacteria and their products, including, 
metabolites, DNA and cell wall components.21  When Lactobacillus acidophilus 
and Lactobacillus casei were administered, the macrophages exhibited increased 
phagocytic abilities.22 In healthy individuals, probiotics are shown to upregulate 
the expression of phagocytosis receptors in neutrophils and strengthen natural 
killer (NK) cell activity.23,24 Most importantly, they are able to modulate immune 
response through adaptive immunity.25 Cosseau et al. (2008) proposed that S. 
salivarius K12 is not only tolerated by the host but also promotes homeostasis and 
cellular health, leading to the protection of host tissues from damage caused by 
other immunostimulatory cells and products.26  Based on their in vivo study, Della 
et al.(2007) found that Lactobacillus brevis significantly decreased inflammatory 
markers in saliva, such as metallo-proteinase, nitric oxide synthase activity, PGE2 
and interferon γ levels.27 
1.2 Probiotics and Peri-Implant Conditions 
 




These encouraging results have kindled growing interest in probiotics and 
very recently, authors have begun to expand the scope of probiotic research to 
look into peri-implant diseases.  Peri-implant diseases exist as either peri-implant 
mucositis or peri-implantitis.  Though both are inflammatory reactions in the 
tissues that surround an implant, peri-implant mucositis is defined as the result of 
inflammation confined to the tissues that surround the implant with no loss of 
supporting bone after initial bone remodeling, while peri-implantitis is an 
inflammatory process characterized by both soft tissue inflammation and 
progressive loss of supporting bone in relation to radiographic bone level one year 
after implant supported prosthetic delivery.28 While measuring the true prevalence 
for peri-implant diseases remains controversial in today’s literature, it is still 
broadly regarded as highly prevalent. Zitzmann and Berglundh’s review 
concluded that up to 80% of all dental implant patients and 50% of all implants 
have peri-implant mucositis while 28-56% of all dental implant patients and 12-
43% of all implants have peri-implantitis.29  The literature has demonstrated that 
the microbiota associated with peri-implantitis is more complex, consisting of 
mainly anaerobic gram-negative bacteria versus microbiota associated with 
healthy peri-implant tissues.30 Particularly, Staphylococcus aureus may be a 
critical pathogen in initiating peri-implantitis.31,32  Studies found that tissue 
destruction both clinically and radiographically, was significantly more 
destructive for peri-implantitis lesions versus periodontitis.33,34 The size and 
extent of the inflammatory cell infiltrates in the connective tissue were greater in 




protective tissue capsule that separates lesion from alveolar bone did not occur for 
peri-implantitis lesions.35 In addition, animal studies demonstrated that the disease 
continued to progress insidiously even after post-ligature removal in experimental 
peri-implantitis.36-38 
1.2.2. Treatment for Peri-Implant Diseases   
 
Peri-implant disease is an important pathology worth understanding owing 
to its prevalence and incidence.  A full 80% of subjects and 50% of implants were 
reported to have peri-implant mucositis while peri-implantitis affects a range 
between 28 and 56% of subjects and between 12 and 43% of implant sites.39  
Since the main etiology for peri-implant disease is the development of bacterial 
biofilm on the implant surface, the goal of treatment of peri-implant disease is to 
remove the bacterial biofilm and disinfect the implant surface.40 Unfortunately, 
the screw threads and surface roughness  of implants make decontamination of the 
implant especially difficult.  Several studies using the non-surgical approach have 
demonstrated promising results in controlling inflammation with decreased 
bleeding on probing and may heal peri-implant mucositis lesions. Nonetheless, 
using this modality still gives unpredictable results in treating peri-implantitis 
lesions.41  A systemic review by Giacomo et al. concluded that non-surgical 
therapy of peri-implantitis had limited efficacy for treating peri-implantitis.42  
However, among various non-surgical options investigated, mechanical 
debridement and adjunctive measure appeared to provide slightly greater benefits.  
Specifically, Gomi et al. found that using systemic azithromycin, along with 




reduction of 0.96 +/- 0.4 mm in the test group versus control after the 1 year 
follow up.43  Nevertheless, it is concerning that the incidence of peri-implantitis 
seems to further increase as more and more implants are placed by a number of 
clinicians with various degree of expertise.  The11th European Workshop of 
Periodontology raised awareness for research to recognize effective protocols in 
treating peri-implantitis.44  Current research has, however,  still failed to identify a 
gold standard in treating peri-implantitis.  Though several protocols were 
documented including nonsurgical, surgical, resective, regenerative and combined 
approaches, the best management in treating peri-implantitis remained a mystery.  
Perhaps these results from the heterogeneity of the study designs, patient profiles, 
defect characteristics, implant and prosthesis design, clinician experience and 
skills, or disease definitions.  The systematic review and meta-analysis of Chan et 
al. attempted to assess the surgical management of peri-implantitis.45  They 
concluded that the use of grafting material and barrier membranes gave greater 
pocket depth reduction and radiographic bone fill, leading to a PD reduction of 
33.4% to 48.2%.45  However, the authors recognized that more high quality 
comparative studies need to be conducted before this conclusion can be 
supported.  However, the newest systematic review published by Roccuzzo et al. 
analyzed clinical outcomes of peri-implantitis treatment and supportive care, 
which seemed to give hope in treating this tricky lesion.46  Studies with >10 
patients with at least 3 years follow up were searched and analyzed looking at 
cumulative survival at both implant and patient level.  This systematic review 




supportive care program that involves professional biofilm removal demonstrating 
that over 90% of implants and over 85% of patients who received the supportive 
care treatment could retain their implants successfully after 5 years.46  It is 
important to note that 20% of the included studies were found using grey 
literature and that the definition of survival did not include tissue health, tissue 
appearance or patient satisfaction.46  Thus, a surviving implant in one patient 
compared to another surviving implant in a different patient may be extremely 
different, serving as yet another limitation of this review. A time passes, we 
incrementally learn more and more about peri-implantitis lesions. 
Notwithstanding this growth in relevant studies, we still suffer from lack of 
comprehensive evidence to support recommending one treatment over another in 
the management of peri-implantitis lesions. 
 
1.2.3. Probiotics and their Effects on Peri-implant Mucositis and Peri-
implantitis: 
Only a few studies have investigated the effects of oral probiotics for peri-
implant mucositis and peri-implantitis.   In a very recent study, Tada et al.  
showed that probiotics prevent inflammation by affecting host responses rather 
than improving microbial flora in peri-implant sulci in peri-implantitis patients.47   
In 2015, Flichy-Fernandez et al. carried out a double blind, placebo-controlled 
cross-over study evaluating the effects of taking Lactobacillus reuteri on 
edentulous implant patients by comparing the peri-implant health of those without 




that both groups demonstrated improvements in plaque, diminished probing 
depth, gingival index and gingival crevicular fluid levels with decreased cytokine 
levels.48  Hollstrom et al. evaluated the effects of probiotics as an adjunct to 
mechanical debridement for peri-implant mucositis lesions.49  They administered 
topical oil application followed by Lactobacillus reuteri to patients with peri-
implant mucositis for 3 months and clinically evaluated the patients’ probing 
depths, plaque index, bleeding on probing and subgingival microbiota using 
checkerboard DNA-DNA hybridization.49  While all patients improved clinically, 
they found no significant differences between the two groups in their subgingival 
microflora and levels of inflammatory mediators in GCF.49  In contrast to the 
study by Flinchy-Fernandez et al., Hollstrom et al. concluded that probiotic 
supplements did not improve clinical, microbial or inflammatory variables of 
peri-implant mucositis as opposed to a placebo.48-49  The newest study 
investigating peri-implant mucositis and the effects of probiotics was conducted 
by Pena et al. in 2017.50  They investigated, both clinically and microbiologically, 
the effects of oral probiotics in 50 patients  with peri-implant mucositis lesions.  
The test group involved mechanical debridement with 0.12% chlorhexidine 
mouthwash plus the administration of a Lactobacillus reuteri tablet, while the 
control group substituted the oral probiotic tablet for a placebo.50  After following 
the patients for 135 days, they concluded that the probiotics did not appear to give 
any additional clinical or microbiological benefit but that the treatment with 
mechanical debridement plus chlorhexidine rinse was effective in decreasing 




effects of oral probiotics for peri-implant mucositis lesions are still controversial 
and that studies assessing the effects of oral probiotics on peri-implantitis lesion 
are even more scarce with limited evidence.  To the best of our knowledge, only 
one study has, so far, published on this topic.  A triple blind randomized clinical 
trial published by Galofre et al. assessed the effects of probiotic administration of 
Lactobacillus reuteri on both mucosisits and peri-implantitis.51 A total of 44 
patients, 22 of whom had mucositis and 22 of whom had peri-implantitis, were 
recruited in this study. For both mucositis and peri-implantitis lesions, it was 
found that  L. reuteri, together with mechanical therapy, gave additional 
improvement compared to treating with only mechanical therapy for all clinical 
parameters, such as bleeding on probing and probing pocket depth.51  However, 
interestingly, very limited effect microbiologically was observed, as the only 
significant decrease in bacterial load was for P. gingivalis in mucositis lesions.5 
 
1.3. Oral Microbiome and Peri-Implant Tissues 
1.3.1. Background: Oral Microbiome  
The oral cavity is continuously colonized by various microorganisms, 
collectively called the oral microbiome.  This microbiome resides in the oral 
cavity and consists of different anatomic structures in the form of biofilm which 
produces an equilibrium that maintains health.  However, ecological shifts in the 
microbiome lead to development of pathogenic species that may cause 
destruction.  Biofilm not only occurs on teeth and mucosa, but also it also 
develops in artificial structures, such as, prosthesis and implants.  Thus, oral 




sensitive to immune cells and other anti-microbial agents.52  Currently, the 
ecological hypothesis of plaque can explain how oral biofilm causes diseases, 
such as caries, periodontitis or peri-implantitis by the interactions between 
microorganisms and the host which then establish the state of either health or 
diseases.53 Recent studies have suggested a new model of periodontal disease 
pathogenesis whereby individual pathogens do not cause chronic periodontitis, 
but rather, a polymicrobial synergy and dysbiosis combined with an unbalanced 
immune response is responsible for inflammation-mediated tissue damage.54  For 
example, changes in microflora environment as influenced, for example, by diet, 
pH, oral hygiene regimen and use of antibiotics, immune system integrity may 
also alter biofilm composition.  As a result of these changes, certain species of 
bacteria may exhibit greater virulence thereby allowing opportunist 
microorganisms to cause disease.  
 
1.3.2. Differences between peri-implant tissues versus periodontal tissues: 
Though similarities exist in microbial colonization during biofilm 
formation between peri-implant tissues and periodontal tissues, fundamental 
differences exist.  Peri-implant tissues lack Sharpey fibers, i.e., collagen fibers of 
the submucous connective tissue situated perpendicular in periodontal tissues.  
More specifically, collagen fibers surrounding implant body are arranged parallel 
to the implant surfaces.  This allows a greater gap compared to the gingival sulcus 
leading to easier penetration of microorganisms.  Moreover, peri-implant tissues 




submucosal tissues to be more susceptible to microorganisms.  In addition, blood 
supply is decreased, leading to fewer nutrients and host anti-bacterial system 
represented by immune cell infiltrates that are crucial especially in the early 
stages of infection .55 
 
1.3.3 Peri-Implant Microbiome Development:  
So far, researchers have reached no consensus on the exact time that the 
peri-implant microbiome becomes established, but Persson net al. believed that 
implant contamination happens during implant surgery and subsequent prosthetic 
component delivery.55.   This agrees with van Winkelhoff and Winkel’s who 
reported the presence of  Peptostreptococcus micros, Fusobacterium sp. and 
Prevotella intermedia after implant installation.56  Salvi et al. discovered that 
bacteria associated with periodontitis such as Porphyromonas gingivalis, 
Tannerella forsythia and Treponema denticola were found in the same prevalence 
30 minutes or 1 year after implant installation, with P. gingivalis being the most 
prevalent species in both teeth and implants.57  After just after a few weeks 
following implant installation, other studies found the presence of 
microorganisms in peri-implant groove or from the surface of implants.58-60  Many 
believed that peri-implant microbiome establishment occurs via transmission of 
microbiome from teeth to implants.  Gerber et al. believed that the oral 
microbiome present before implant insertion can determine the microbiome 
composition in peri-implant sites.  They proposed that patients with a history of 




theory is supported by Botero et al. who found that in partially edentulous patients 
with periodontitis who had dental implant rehabilitation exhibited pocket and 
bone loss around implants with high levels of periodontal pathogens.  In fact, 
facultative anaerobes were found after 6 months of implant placement in the 
subgingival flora which support the theory that teeth may serve as a reservoir in 
transmitting pathogens to implants.  On the other hand, patients with history of 
periodontitis that is aggressively monitored and controlled did not have changes 
or inflammation after osseointegration of their implants.63 
 
1.3.4 Oral microbiome associated with dental implants  
In healthy peri-implant sites, a high proportion of Gram positive coccus if 
found, but for peri-implantitis cases, high amounts of Aggregatibacter 
actinomycetemcomitans and P. gingivalis were discovered, supporting the 
argument that these are the predominant microorganisms responsible for the 
destructive nature of peri-implantitis lesions.64-65  Other species, such as 
Fusobacterium, Pseudomonas aeruginosa and T. forsythia in symbiosis, were also 
discovered in peri-implantitis sites.66  Kohavi et al. suggested that the subgingival 
microbiome is similar in teeth and implants as similar amounts of A. 
actinomycetemcomitans and A. viscosus were  found in supragingival biofilm of 
teeth (92% vs. 57%) and implants (90% vs. 73%).67  Quirynen et al. supported this 
suggestion in 2006 by using molecular biology techniques and found small 
differences in microflora between teeth and implants.57  Moreover, Kohavi et al. 




microbiome composed of mainly Gram positive coccus with little amounts of 
spirochetes and mobile bacilli.67  Then Quirynen et al., along with similar studies, 
discovered high levels of bacteria associated with periodontitis and peri-
implantitis in totally edentulous patients.59,68,69.  Other studies reported high levels 
of the red and orange complexes, such as, P gingivalis, T. forsythia, T. denticola 
and F. nucleatum, were in the subgingival biofilm of peri-implantitis sites.70-71  
However, Zhuang et al. reported differences between periodontitis and peri-
implantitis for pathogens in terms of prevalence.72  For example, levels of P. 
gingivalis and F. nucleatum were significantly associated with periodontitis but 
not associated with peri-implantitis.  On the other hand, A. 
actinomycetemcomitans was associated with both periodontitis and peri-
implantitis.72  These differences among studies may be due to the heterogeneity of 
the studies and differences in methodologies for pathogen identification.73  
However, one can still conclude that there appear to be differences between 
healthy implants versus implants with peri-implantitis both in supra and 
subgingival biofilm.  Overall, observational studies revealed that peri-implantitis 
was frequently associated with opportunistic pathogens such as pseudomonas 
aeruginosa and Staphylococcus aureus, fungal organisms such as candida albicans 
and viruses like human cytomegalovirus  and Epstein Barr virus.74  Although the 
submucosal microbiota of peri-implantitis lesions has not been extensively 
investigated with culture independent techniques, it is clear that peri-implantitis 




his 2017 world workshop narrative review on peri-implantitis that the “microbial 
picture associated with peri-implantitis should be regarded as incomplete”.74 
 
1.4. Current Study 
1.4.1. Purpose 
Currently, no gold standard guides the treatment of peri-implantitis 
lesions.  Since bacteria were believed to be the main causative factor for 
periodontal and peri-implant diseases, it is crucial to examine the role of 
microorganisms in the development and progression of peri-implantitis.  
Therefore, the present study aimed to examine and compare the range of 
microorganisms harvested from healthy, periodontitis and peri-implantitis sites 
and to examine if probiotics, taken orally, as an adjunct to non-surgical treatment 
would affect the microbiome within the oral cavity compared to placebo. In 
addition, to examine the effects of adjunctive probiotic intake on GCF/PICF 
inflammatory markers. To accomplish this, clinical, inflammatory and 
microbiological effects of oral probiotics were tested as an adjunct to non-surgical 
therapy in peri-implantitis lesions in a 90-day period while samples from healthy, 
periodontitis and peri-implantitis sites were compared.    
 
 
1.4.2. Specific Aim 
 




1. To evaluate the clinical, microbiological and biological effects of oral 
probiotics used as an adjunct to non-surgical therapy in patients with peri-
implantitis lesions.  
2. To evaluate these effects in probiotic group compared with placebo group. 
3. To compare the effects in peri-implantitis sites with healthy and periodontitis 
sites. 
Hypothesis: Patients receiving oral probiotics as an adjunct to non-surgical 
periodontal therapy for 90 days will demonstrate better clinical, microbiological 
and inflammatory outcome at 90 days compared to placebo group. 
 
Chapter 2: Materials and Methods 
 
2.1: Regulatory approvals: 
This study was designed and performed as a double-blind randomized 
clinical trial of 90 days in duration.  The study protocol was submitted to and 
approved by the Institutional Review Board for Research with Human Subjects 
(IRB) of Nova Southeastern University, Florida, USA.   
2.2. Study Design 
 
This is a pilot study to investigate the clinical effects of orally 
administered probiotics as an adjunct to non-surgical treatment on peri-
implantitis lesions.  It also aims to assess the microbiological composition of 
healthy, periodontitis and peri-implantitis sites of the samples collected and 
determine if adjunctive probiotics had any anti-inflammatory effects on 




2.3:  Patient Selection: Inclusion and Exclusion Criteria: 
Patients with peri-implantitis were enrolled in the post graduate 
periodontics clinic at the College of Dental Medicine of Nova Southeastern 
University.  
Inclusion criteria: 
 1. Patients that have one or more implants diagnosed with peri-implantitis  
a) Peri-implantitis is defined as inflammation in peri-implant mucosa 
and subsequent progressive loss in relation to radiographic bone level at 1 year 
after implant supported prosthetic delivery.  This definition is based on the 
2017 World Workshop on the classification of Periodontal and Peri-implant 
diseases and conditions (Swartz 2017 classification). 
2. Age ≥ 18 years old 
 




1. Uncontrolled medical conditions  
2. Pregnant or lactating females  
3. Use of antibiotics for the last 3 months. 
4. Subjects treated for ≥ 2 weeks with any medication known to affect soft tissue 
inflammation, such as, cyclosporine, phenytoin, or Coumadin. 
5. Patients taking bisphosphonate medication 
6. Patients diagnosed with aggressive periodontitis 




The samples were taken from patients affected by peri-implantitis who 
attended the post graduate periodontics clinic of the College of Dental 
Medicine at Nova Southeastern University.  A total of 13 systemically healthy 
patients were initially recruited but 4 subjects dropped out of the study due to 
reasons such as loss of implants, recent surgery requiring antibiotics and 
scheduling conflicts not being able to keep up with follow-ups. Thus, the study 
was ultimately made up of a total of 9 patients.  They were randomly assigned 
to two different treatment groups: the test group (probiotics) and controlled 
group (placebo).  The study was conducted over a 90-day period with each 
patient coming in for four appointments total.  Subjects were advised to 
maintain their usual diet during the study period but to avoid intake of 
fermented milk products and foods that may contain high quantities of 
fermentable carbohydrates.  Moreover, at the end of each subject completion of 
90 days, each subject was given the opportunity to re-enroll in the study after a 
4-week wash-out period.  Patient has the right to either continue or decline the 
offer.  If they decide to re-enroll themselves for another 90-day period of the 
experiment as a new subject of the study, they were then randomly assigned to 
either the test or controlled group.  Ultimately, four out of the nine participants 
decided to re-enroll in the study after wash-out period making up a total of 13 
subjects for this pilot study.  
 




Two designated examiners (PH and JW), both appropriately trained and 
calibrated clinicians, collected clinical, radiographic and microbiological data.  
Six sites (disto-buccal, buccal, mesio-buccal, disto-lingual, lingual and mesio-
lingual) were recorded for periodontally healthy (n=13), periodontitis (n=13) 
and peri-implantitis sites (n=18) for each subject.  Total samples for sites were 
(n=44) per subject.  The subjects were clinically assessed at baseline and 90-
days using UNC probe (UNC, Hu-Friedy, Chicago, Il, USA), which has 
marked millimeters from 1 to 15 was used to conduct these measurements. The 
implant shoulder was used as a landmark for clinical attachment level and 
mucosal recession.   
The clinical measurements taken were as follows:  
• Probing depth (PD): in millimeters 
• Clinical Attachment Level (CAL): The implant shoulder was used as a 
landmark for the clinical attachment level and for the mucosal recession. 
• Bleeding on Probing (BOP) 
• Modified Plaque Index 
• Gingival Index 
 
The microbiological samples taken were as follows:  
• Subgingival plaque sampling:  Subgingival plaque samples were collected 
from 3 sites (periodontally healthy site, periodontitis site, peri-implantitis site) 
using a sterile Gracey curette at baseline and at 90 days and transported into 




mM EDTA, pH 7.6).  Before collecting subgingival plaque, supragingival 
plaque was removed by sterile gauze and scalers.  Sites of collection for 
subgingival plaque were isolated with sterile cotton roll.  
 
• Peri-implant crevicular fluid (PICF) and gingival crevicular fluid (GCF) 
sampling:  
PICF and GCF samples were collected from the implant site with peri-implantitis, 
tooth with periodontitis (if existed in patients’ mouths) and periodontally healthy 
tooth using a PerioPaper® (Oraflow, Inc) placing in the crevice for 30 seconds. 
Immediately after the collection, the volume of collected fluid in the paper points 
was measured by using a Periotron 6000 (Oraflow). The PerioPaper® were 
collected in a fresh tube (1.5 ml Eppendorf tube) and saved at -80°C to determine 
measurement of biomarkers related to the inflammation and bone tissue destruction 
using ELISA. 
 
2.6: Tablets: Test Group (Probiotics) versus Placebo Group 
Probiotics used for the test group: 
• Probiotic tablets (Hyperbiotics PRO Dental tablets) were made in 
Washington State then tableted in a Good Manufacturing Practice (GMP) 
certified facility in Colorado.  The content of one tablet is composed of 
proprietary probiotic blend of 3 billion CFU (S. salivarius K 12, S. 
salivarius M18, L. reuteri, L. paracasei) and zinc amino acid chelate of 




iron free, and gluten-free. It has no wheat, no nuts, no preservatives, no 
sugar and no artificial colors, flavors and sweeteners. 
Placebo used for the control group: 
• Hyperbiotics Inc, the company that manufactured the test tablets, also 
manufactured the placebo tablets that contained the same ingredients, 
except the active ingredient of probiotic bacteria.  
2.7 Timeline for the study: 
Visit 1: Data collection + Non-surgical treatment and start of tablet 
consumption  
Subjects’ medical and dental history was obtained, reviewed and kept in each 
study file stored in a secured cabinet.  They received a complete periodontal 
exam where the designated examiner measured clinical parameters listed above 
in section 2.5.  Subgingival plaque was collected with a sterile Gracey curette 
in 3 sites: healthy site (≤ 3mm PD), periodontitis site (≥5mm with BOP), and 
the peri-implantitis site at baseline and 90 days. In addition, PerioPapers was 
used to collect PICF & GCF samples at baseline and 90 days. Last, 
standardized digital radiographs (bitewings and PAs) of the peri-implantitis 
lesions were taken.  
 
Full mouth non-surgical debridement (where necessary scaling and root planing – 
SRP) were performed and subjects were randomly assigned to a treatment group 
(placebo or test group).  The randomization was performed by means of computer-




allocations were assigned.  The record book remained in the hands of the PG 
periodontics clinic coordinator, who did not share this information with patients or 
clinicians.   One bottle of 30 tablets containing either placebo or probiotics, was 
given to the patients.  Proper administration instructions were given to the patients.  
– Both groups were instructed to take 2 tablets once per day.  The subjects were 
asked to bring the tablets left with them in the bottle at each follow-up appointment. 
 
Visit 2: 30 days after visit 1: 
Subjects reported back to PG periodontics clinic and their medical histories 
were updated.  Oral hygiene was checked, and oral hygiene instructions were 
given and reinforced.  Patients were reminded to continue taking the tablets.   
 
Visit 3: 60 days after visit 2: 
Subjects reported back to PG periodontics clinic and their medical histories 
were updated. Oral hygiene was checked, and oral hygiene instructions were 
given and reinforced.  Patients were reminded to continue taking the tablets.   
 
Visit 4: 90 days after baseline (final appointment): 
Subjects reported back to PG periodontics clinic and medical history was updated.  
They returned the empty bottles to ascertain the compliance of the patients.  They 
received a complete periodontal exam where the examiner would measure clinical 
parameters listed above in section 2.5.  Subgingival plaque was collected with a 




peri-implantitis sites.  In addition, Perio papers were used to collect PICF and GCF. 
Last, standardized digital radiographs (bitewings and PAs) of the peri-implantitis 
lesions were taken.   
 
2.8. Statistical Analysis and Data Interpretation: 
 
Clinical data was analyzed with one-way ANOVA with p-value <0.05 as 
being statistically significant to compare statistical differences between treatment 
groups.  In addition, plaque samples were shipped to the Laboratories of 
Molecular Anthropology and Microbiome Research (LMAMR, Director, Dr. 
Cecile Lewis) at the University of Oklahoma for 16S-ribosomal RNA (rRNA) 
based microbiome sequencing service. The PICF/GCF samples were analyzed to 
measure TNF-α, IL-β, MMP-9 and RANKL in the collected samples using ELISA 
in the Department of Periodontology at NSU College of Dental Medicine.  
 
 
Chapter 3: Results 
 
3.1 Clinical outcomes:  
 
A) Pocket depth:  
PD measured at baseline showed significantly higher levels in 
periodontitis and peri-implantitis group compared to that in periodontally healthy 
group. The trend of higher PD levels in periodontitis and peri-implantitis were 
retained at 90 days after the non-surgical treatment followed by oral 
administration with probiotic or placebo tablets. We did not find any statistically 




periodontitis and peri-implantitis groups in Day-90 compared to baseline (Figure 
1, Table 1 and 2) 
 
B) GCF/PICF:  
It is well established that flow rate of GCF/PICF and severity of 
periodontitis/peri-implantitis at the disease affected site are positively correlated. 
In the present study, GCF and PICF were collected using PerioPaper by inserting 
it into the periodontal and peri-implant sulcus for 30 seconds. Subsequently, the 
volume of fluid collected in PerioPaper was measured using Periotron 4000. We 
could not find any significant difference in the levels of GCF/PICF measured at 
baseline. However, GCF volume as well as PICF volume measured in 
periodontitis and periimplantitis at Day-90 were both significantly higher than 
GCF measured in periodontally healthy sites at Day-90.  There was no 
statistically significant difference in the GCF and PICF volume between the 
probiotic and placebo groups at Day-90 (Figure 2, Table 1 and 2) 
  
C)  Clinical Attachment Level (CAL):  
CAL was also measured at Baseline and Day-90 on all study participants. 
The levels of CAL were significantly higher in the sites of periodontitis as well as 
peri-implantitis than periodontally healthy sites at both baseline and Day-90. 
Between two different diseased sites, the CAL values were higher in peri-
implantitis than periodontitis (no significant difference, Baseline: P=0.62, Day-




measured for all three sites, i.e., healthy, periodontitis and peri-implantitis sites 
between baseline and Day-90 (healthy: P=0.81, Periodontitis: P=0.43, Peri-
implantitis: P=0.98), indicating non-surgical treatment was not effective in CAL 
changes. Finally, adjunctive oral administration of probiotic tablets did not show 
any statistically significant difference on CALs compared to placebo group. 
(Figure 3 and Table 1 and 2) 
 
3.2 Pro-inflammatory biomarkers in GCF/PICF 
Using the GCF/PICF collected at baseline and day-90, pro-inflammatory 
cytokines and bone/tissue destructive factors produced in each site were measured 
using Luminex Multianalyte System. More specifically, TNF-a, IL-b, RANKL 
and MMP-9, were measured in GCF/PICF.  At baseline, there was an increasing 
trend of TNF-a IL-1b and RANKL productions in both periodontitis and 
periimplantitis sites compared to healthy sites, indicating that inflammatory 
responses are induced in those diseased sites. Such a trend of higher production in 
periodontitis and peri-implantitis sites than periodontally healthy sites was not 
detected for MMP-9 measured at baseline. (Figure 4,5,6, and 7) Among those four 
factors detected in GCF/PICF, only TNF-a showed some responses to treatment. 
In the GCF collected from periodontitis sites at Day-90, non-surgical treatment 
followed by either oral administration with probiotic or placebo tablets suppressed 
significantly the production of TNF-ain periodontal pocket, suggesting that non-
surgical treatment was effective in down-regulating the production of 




sites. However, in the PICF collected from peri-implantitis sites at Day-90, non-
surgical treatment followed by oral administration with probiotics, but not 
placebo, showed  significant suppression of TNF-a production, indicating that 
adjunctive oral probiotic administration  may be effective in down-regulating the 
production of TNF-a levels in PICF in peri-implantitis lesions. (Figure 4, 5, 6, 
and 7) 
 
3.3  Microbiological analysis of subgingival plaque samples in periodontally 
healthy, periodontitis and peri-implantitis sites 
According to the 16S rRNA sequence performed for dental/peri-implant 
plaque, which is commonly used for identification, classification and quantitation 
of microbes within the plaque, we identified a total of 838 bacterial species. The 
16S rRNA gene is the DNA sequence corresponding to rRNA encoding bacteria, 
which exists in the genome of all bacteria and highly conserved, specific to each 
bacterial species, and the data base include the all species of bacteria of which 
16S rRNA was already clarified. Nonetheless, we could not detect any of the four 
probiotics administered orally via probiotic tables at Day- 90 samples, including, 
S. salivarius K 12, S. salivarius M18, L. paracasei, and L. reuteri, suggesting that 
probiotic bacteria did not colonize in any of sites tested.  
 
The formation of oral bacterial biofilm, which is responsible for onset and 
progression of periodontitis, was thoroughly studied by Socransky’s group at the 




theory that the tooth surface is consecutively colonized by distinct complexes of 
bacteria which were color coded in following order: 10 yellow/purple, 2) orange 
and 3) red. For instance, in the red complex, three periodontal pathogens, 
Porpyhromonas gingivalis, Treponema denticola, and Tannerella forsythia, are 
included. According to their theory, the clinical symptoms of periodontal 
infection usually reflect the amount and composition of dental plaque harbored 
around the tooth. This theory of bacterial settlement was also translated into 
dental implant infections (29238198). The elevated species in microbial flora in 
the peri-implant lesions compared to healthy peri-implant tissue were found to be 
similar to those found elevated in periodontitis compared to healthy periodontal 
tissue, including the red complex bacteria and orange complex species 
(Fusobacterium and Prevotella intermedia) defined by Socransky’s color 
complex theory (PMID: 27833735, 25622536, 26424287, 26252036). Therefore, 
we have evaluated the effects of orally administered mixed probiotics on the 
possible alteration of different color complex bacteria. 
 
According to 16S rRNA sequence results, at the baseline, significantly 
elevated relative sequence counts of red complex bacteria, including, 
Porpyhromonas gingivalis, and Tannerella forsythia were found in peri-
implantitis (both Pg and Tf) and periodontitis sites (Tf) compared to healthy sites 
(Figure 9). Among 6 bacteria in the orange complex, only Parvimonas micra 
showed the significantly higher relative sequence counts in peri-implantitis 




corrodens and Campylobacter concisus, showed the decreased incidence in 
periodontitis and peri-implantitis sites compared to healthy sites (Figure 11). In 
the yellow complex, the relative sequence counts of Streptococcus sanguinis was 
significantly lower than that of healthy site (Figure 12). In sum, the color complex 
distribution in the microbiome of peri-implantitis lesion was similar to the 
Socransky’s theory established for periodontitis.  
 
The effects of oral administration of probiotics on the relative sequence 
count of each bacteria in different color complexes were determined in the plaque 
samples collected from periodontally healthy, periodontitis and peri-implantitis 
sites at Day 90, in comparison to the placebo control. There was no significant 
effect of probiotics used in this study on the relative sequence count of any 
bacteria in red and orange complex compared to placebo or baseline level. 
Instead, adjunctive probiotics significantly increased the relative sequence count 
of Prevotella intermedia in periodontitis site compared to placebo control or 
baseline in the orange complex. On the other hand, relative sequence count of 
Campylobacter concisus in green complex, Actinomyces species in yellow 
complex and Actinomyces graevenitzii in purple complex were significantly 
increased in the peri-implantitis sites by the oral administration of probiotics at 
Day-90, but not in control group. These results indicated that probiotics appeared 
to elicit the host beneficial influence to restore the healthy, more symbiotic 
microbiome in the peri-implantitis sites by promoting the population sizes of 




this study did not affect the population size of pathogenic complexes (red and 
orange complexes).    
 
Chapter 4:  Discussion  
 
As infectious diseases present a problem in the current healthcare society, 
bacterial resistance to antibiotics became a realistic concern.  It is true that, after 
bacterial resistance was reported to Daptomycin, an alternative to Vancomycin 
that had been used as the last resort antibiotics for MRSA treatment, 
pharmaceutical industry has never developed any novel class of antibiotics that 
can kill Daptomycin-resistant MRSA. Thus, alternative therapies such as 
probiotics became more of interest in recent research.  Current research 
investigated the use of L.reuteri as an adjunct to non-surgical therapy in treating 
gingivitis and periodontitis and found clinical and microbiological improvement 
in addition to the benefit of implementing mechanical treatment alone.75,76  A 
recent systematic review and meta-analysis published in March 2020 evaluated 
specifically, the effect of probiotic Lactobacillu, in the nonsurgical management 
of peri-implant diseases found that there was a slight reduction of probing depth 
after treatment termination but concluded that overall, Lactobacillus gave limited 
benefits in peri-implant mucositis.77  This systematic review included 7 studies 
with only one of them looking at the effect of Lactobacillus on peri-implantitis 
lesions while the other studies focused only on peri-implant mucositis lesions.77  
However, it is noteworthy that  the evidence withdrawn from those 7 published 
studies is weak, due to the small sample sizes which did not provide sufficient 




in managing peri-implant mucositis and peri-implantitis with lactobacillus in 
conjunction with non-surgical treatment, this result can only be considered 
preliminary due to its small sample size.77  Thus, more studies are needed 
especially for investigating the potential benefit of oral probiotics in treating peri-
implantitis.  To the best of our knowledge, there was only one published study by 
Galofre et al. to date that examined on the oral intake of probiotic as an adjunct 
treatment to non-surgical mechanical therapy.51 They concluded that the 
probiotic, L. reuteri led to a statistically significant improvement for clinical 
parameters such as bleeding on probing, probing pocket depth while 
microbiologically, there were no effect on the bacterial load for peri-implantitis 
sites.51  However, the subjects only took the oral probiotic for 30 days and real-
time PCR was used to quantify bacterial loads of only 9 bacteria in the red and 
orange complexes.51  Contrast to the above noted published studies that evaluated 
the possible therapeutic effects of administrating single strain of L. reuteri,   the 
present study, for the first time, utilizes a mixture of oral probiotics that contains 
three additional strains of bacteria including  S. salivarius K 12, S. salivarius M18 
and L. paracasei, in addition to the conventionally used  L. reuteri.  In Chapman 
et al.’s review in comparing mixture of probiotic strains versus single strain in 
efficacy, it was concluded that probiotic mixtures were more effective against a 
wide variety of end points including irritable bowel syndrome, atopic diseases, 
immune function, respiratory infections and more.78. It is, then, conceivable that 
the superior efficacy of mixed probiotic strains may be attributed to synergistic 




plausible that, because of mixture of different strains, the increase total number of 
probiotic bacteria used in those clinical studies are responsible for the pronounced 
clinical efficacy compared to that used single probiotic strain.  Thus, with the 
purpose to augment the efficacy of the oral probiotics as much as possible,  the 
present study used a higher dosage of mixed probiotic strains compared to other 
published studies; more specifically, the patients were instructed to take 2 tablets 
of 3 billion colony forming units (CFU) of mixture of four probiotic strains (a 
total of 6 billion CFU), contrast to one tablet containing a single strain of L. 
reuteri (2 hundred million CFU) as implemented by the majority of the 
studies.48,49  Furthermore, this study explored microbiome changes on not only 
peri-implantitis lesions but also, periodontally healthy and periodontitis sites and 
used 16S ribosomanl RNA (rRNA)  sequencing to conduct the microbiological 
analysis.  This metagenomic bacterial sequencing method can better recognize 
poorly described, rarely isolated or phenotypically aberrant strains than classical 
PCR method which may, in turn, lead to identifying novel pathogens and/or 
uncultured bacteria.79  This pilot study concluded that this multiple strain blend of 
probiotics had no statistical significant effects on any of the clinical parameters 
tested including probing depth, GCF/PICF volume and clinical attachment levels 
in the probiotic group compared to the placebo group for peri-implantitis and 
periodontitis sites.  This could be due to no effect of adjunctive use of probiotics 
in peri-implantitis lesion and/or small sample size.  Such findings did not 
correspond to the studies by Galofre et al. and Flichy-Fernandez et al.48,51  Galofre 




probiotic administration whereas  Flichy-Fernandez et al. also reported the 
findings similar to Galofre et al. in peri-implant mucositis sites.48,51  Nonetheless, 
the present results were in accordance with Hallstrom et al. who reported little or 
no effects of probiotics on the clinical parameters in the peri-implant mucositis 
sites.49  Since it is well-accepted that multiple different factors, such as ethnic 
background, gender and age, are also associated with pathogenesis of peri-
implantitis, large scale comprehensive clinical studies are required in future to 
gain insight into the effects of probiotics on the peri-implantitis lesions.    
The key finding of this study is the impact of probiotics on the 
microbiological composition as well as on the production patterns of pro-
inflammatory cytokine TNFa produced in GCF/PICF.  There was no difference in 
the levels of MMP-9 and sRANKL detected in GCF/PICF between the baseline 
(Day-0) and two treatment groups (placebo and probiotics) at Day-90.  Both 
placebo and probiotic groups at Day-90 compared to baseline (Day-0) showed a 
statistically significant decrease in TNF-α levels at periodontitis sites in the 
present study. However, the probiotic group only, but not placebo group, 
demonstrated a statistically significant reduction in PICF TNF-a levels at peri-
implantitis sites at Day-90 compared to baseline.  A  recently published 
systematic review study showed that peri-implantitis sites were associated with a 
significant increase in TNF-a levels compared to healthy implant sites.80-81  
Furthermore, TNF-a levels have been proposed to be used as one of early 
biomarkers to detect the onset of peri-implant diseases that may not be clinically 




impairs the regenerative ability of the peri-implant tissue.  The review also 
illustrated that TNF-alevels increase with the progression of attachment loss 
around implants suggesting that the levels of TNF-a could be proportional to the 
loss of attachment.80  Thus, our findings showing statistically significant reduction 
in PICF TNF-a levels at peri-implantitis lesions of probiotic group indicated that 
administration of oral probiotics may reduce inflammation around peri-implantitis 
sites by shifting the subgingival microbiome towards more symbiotic bacteria. 
Therefore, we speculate that oral probiotic administration as an adjunct to regular 
home care could prevent the progression of peri-implantitis. To test it, large scale 
longitudinal studies are needed to evaluate the effect of this probiotic blend on 
suppression of pathological tissue destruction in peri-implantitis lesions by 
monitoring the level of TNF-a as a pathologic biomarker.   
This study investigated the impact of mixed probiotics on the incidence of 
specific bacteria in the Socransky’s color complexes (red, orange, purple and 
yellow), whereas effects of mixed probiotics on the shift of bacterial phyla in 
microbiome were also monitored.82  Although there were no reduction in the 
incidences of the red and orange complexes, an intriguing trend of elevated 
incidence the commensal bacterial species was detected in peri-implantitis sites, 
but not periodontitis sites, in a manner dependent on probiotics treatment.  There 
was a statistically significant increase in the bacteria from the green, yellow and 
purple complexes namely the Actinomyces species, Actinomyces graevenitzii and 
Campylobacter concius.  Based on Socransky et al., the blue, yellow, green and 




bacteria are known to be the first bacteria to colonize the supragingival and 
subgingival biofilms and are believed to be non-harmful or host-beneficial 
commensal bacteria that are detected as high incidence groups of bacteria in 
periodontally healthy individuals.84  In sum, our findings suggested that, although 
this mixture of probiotics did not suppress the incidence of red and orange 
complexes, it was able to increase the incidence of commensal bacteria that 
represent periodontal health and may therefore help restore the more symbiotic 
oral microbiota from the imbalanced pathogenic microbiota that is in favor of 
upregulating the progression of peri-implantitis. Therefore, we speculate that 
adjunctive and preventive use of oral probiotics can be considered as a treatment 
modality in the future for the treatment of peri-implant diseases.  
 
Moreover, this study was able to compare the microbiome at baseline 
among periodontal health versus peri-implantitis sites and its findings are in 
agreement with several studies that P. micra, T. denticola were associated with 
peri-implantitis lesions while Streptococcus sanguinis was associated with 
health.84.   
 
Furthermore, out of more than the 800 bacterial species detected from the 
16S rRNA gene sequence analysis, there were no specific strains from the oral 
probiotic tablet consumed that were detected.  This could be attributed to the 
colonization effect of oral probiotics may vary among different individuals, 




For example, two different L.reuteri strains were reported to colonize the oral 
cavity of 48-100% of the subjects who consumed the products containing 
them.86,87.  Not only was this a wide range but a mixture of different oral probiotic 
strains could lead to changes in the microbiota overall.  For example, by adding a 
mixture of 7 different Lactobacillus strains, the number of salivary Lactobacillus 
counts increase significantly.41  Maukonen et al. suspected that probiotic bacteria 
may only colonize the oral cavity when they were used in products that are 
contacting the mouth as they did not find any probiotic bacteria that were 
administered through capsules in saliva samples.88. Our finding agreed with this 
phenomenon.  However, Haukioja et al. found in his study that Lactobacillus 
rhamnous survived well in saliva and was even found 3 weeks after discontinuing 
the oral probiotics.89  What was agreed among all the studies investigating 
colonization though was that there was a large variation in binding to saliva-
coated surfaces and buccal epithelial cells and different probiotic strains and their 
interactions could affect the binding tremendously along with high changeability 
among different hosts.89,17, 90.   
This brought the point of one of the limitations of this study being the 
colonization of the multiple blend of bacteria strands over time was not evaluated.  
Though previous literature had suggested that the colonization of L. reuteri in 
subgingival sites start between 2-3 weeks after the start of probiotic treatment and 
remain until 70-75 days post-therapy, it is unknown regarding the duration of 
effect for this particular blend of probiotic strains that this study had 




colonization by each bacterium in the probiotic mixture and evaluate the 
microbiome changes through the time after stopping of the probiotic 
administration.  Such would help to establish the optimal time required for 
treatment and the dosage required for probiotics to take effect.   It is noteworthy 
that, although probiotics were hypothesized to only colonize the oral cavity 
temporarily,  some studies revealed clinical and microbiological improvements 
even when L. reuteri were no longer detected in subgingival samples.91,92  
Another limitation of this study was the relatively low number of total subjects 
(n=15; n=9/group for probiotics and n=6/group for placebo).91,92. According to our 
power calculation, at least n=12/group is required to get the statistically 
significant difference by the intervention provided to the patients with peri-
implantitis. Furthermore, the overhanging prosthesis of the implant crown may 
interfere with the examiner trying to introduce the sampling paper strips 
(PerioPaper) in order to collect the microbiological sample, especially when the 
sulcus was tightly confined.   
Overall, this study demonstrated that the oral administration of probiotic 
mixture for 90 days may help increase the commensal bacteria associated with 
health Nonetheless, longer-term longitudinal studies are needed 1) to determine 
stability of increased commensal bacteria associated with health  2) to ascertain 
the optimal dosage that is needed for the stable change of microbiome towards 
health and 3) to define the duration that the oral probiotics would be able to exert 






Chapter 5: Conclusions   
 
The daily oral intake of the probiotic blend consisting of S. salivarius K 
12, S. salivarius M 18, L. reuteri, L. paracasei, as an adjunct to non-surgical 
periodontal therapy did not improve the clinical parameters for peri-implantitis 
sites.  However, biologically, such an administration of probiotic mixture, but not 
placebo, were able to significantly reduce the PICF TNF-a levels in peri-
implantitis lesions at Day-90 compared to baseline.  This suggested that oral 
probiotics may be indirectly suppressing PICF TNF-a levels possibly decreasing 
the magnitude of inflammation in peri-implantitis lesions.  Moreover, though the 
population sizes of red and orange complex bacteria were not reduced by oral 
administration of probiotic mixture, there was a shift in the population size of 
yellow, blue and purple complex bacteria which may imply that oral probiotic 
mixture may alter the microbiome composition in peri-implant sites  towards 
healthy  symbiotic microbiome.  According to our results, the oral probiotics may 
initiate greater positive microbiological and biological effects in the early stages 
of treatment. However, clinical effects were not shown in the present study as the 
early effects of probiotics. Clinical effects of them may follow in the later stages 
of treatment which can be studied in a long-term clinical study.  Therefore, long-
term longitudinal clinical studies are needed to support these findings as the 
research of oral probiotics’ effect on peri-implant diseases has just emerged in the 
oral science research field.  In addition, there is an overall high heterogenicity 
within the studies published in terms of the dosages and duration used for oral 




strains in probiotic mixture would affect the clinical outcomes as well as 
population size of pathogenic red and orange complexes. 
   
It is still immature to conclude that oral probiotics are able to effectively 
improve peri-implantitis from the present study.  We are confident in stating that 
oral probiotics were able to exert impact on the microbiota within the oral cavity, 
especially in the peri-implantitis lesions within the limitations of the present 
study.  One of the strengths of probiotic approaches is that, unlike notorious 
antibiotics, probiotics do not induce bacterial resistance in the subgingival flora 
even if they were ingested frequently.  Only future research will unveil the 
possible host beneficial property of probiotics in response to peri-implantitis with 
the ultimate goal of developing a side-effect free sufficiently efficient clinical 
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1
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5 3 3 4 2 3 2 4 3 2 4 4 
  
3PI 193 172 8 9 10 9 9 9 10 9 8 9 9 9 
12 B 8H 88 105 3 2 2 3 2 3 1 3 2 2 1 2 
  
3P 147 75 3 3 4 4 3 4 5 5 5 4 4 6 
  
19PI 175 185 4 4 6 5 6 4 5 6 4 4 6 6 
13 B 27H 77 40 3 3 3 2 2 3 2 1 1 2 2 3 
  
5P 169 70 3 2 3 3 2 3 2 1 2 4 3 2 
  
12PI 175 125 9 9 9 6 6 7 9 9 10 8 9 9 
  
13PI 190 190 9 9 7 7 7 6 10 10 9 9 10 9 
 
Note: GCF1b: gingival crevicular fluid volume at baseline; GCF2: gingival crevicular 
fluid volume at final appointment (90 days); PD: probing depth (mm); MB: mesiobuccal; 
MidB: mid-buccal; DB: disto-buccal; ML: mesiolingual; MidL: mid-lingual; DL: disto-
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Note: GCF1b: gingival crevicular fluid volume at baseline; GCF2: gingival crevicular 
fluid volume at final appointment (90 days); PD: probing depth (mm); MB: mesiobuccal; 
MidB: mid-buccal; DB: disto-buccal; ML: mesiolingual; MidL: mid-lingual; DL: disto-


























































































Note: Periodontal status is based on 2018 AAP Periodontal Classification.  All peri-
implantitis lesions qualified as “true peri-implantitis lesions” based on the 2018 AAP 
peri-implant classification definition: 6mm or more with BOP or 3mm radiographic bone 
loss.  Peri-Implantitis status is further defined based on Froum & Rosen’s classification to 























1 33 M Non-
smoker 
S III, G C advanced 
2 70 M Non- 
smoker 
S III, GB moderate 
3 60 F Non-
smoker 
S III, GB moderate 
4 72 M Non-
smoker 
S III, GB advanced 




S III, GB moderate 
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Note:  Periodontal status is based on 2018 AAP Periodontal Classification.  All peri-
implantitis lesions qualified as “true peri-implantitis lesions” based on the 2018 AAP 
peri-implant classification definition: 6mm or more with BOP or 3mm radiographic bone 
loss.  Peri-Implantitis status is further defined based on Froum & Rosen’s classification to 















1 70 M Non-
smoker 
S II, GB moderate 
2 63 F Non-
smoker 
S III, GB moderate 
3 81 M Non-
smoker 
S III, GB moderate 
4 65 M Non-
smoker 
S III, GB advanced 




S III, GB moderate 
6 65 M Non-
smoker 
S III, GB advanced 
7 63 F Non-
smoker 
S III, GB moderate 
8 70 M Non-
smoker 
S II, GB moderate 


















































Figure 1: Pocket depths (PD) comparing Group A (probiotic-test) versus Group B 
(placebo-control).  No statistically significant difference between Day-0 and Day-90 in 
healthy, periodontitis and peri-implantitis sites and between probiotic and placebo 
groups.  





































Healthy Perio PI Healthy Perio PI
PD
Group A Group B
Day 0 Day 90


















































Figure 2: Gingival crevicular fluid (GCF/PICF) volume comparing Group A 
(probiotic-test) versus Group B (placebo-control). No statistically significant 
difference between Day-0 and Day-90 in healthy, periodontitis and peri-implantitis sites 
and between probiotic and placebo groups. Periodontally healthy sites (Healthy); 
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Figure 3: Clinical attachment level (CAL) comparing group A (probiotic-test) 
versus Group B (Placebo-control). No statistically significant difference between Day-0 
and Day-90 in healthy, periodontitis and peri-implantitis sites and between probiotic and 
placebo groups. Periodontally healthy sites (Healthy); Periodontitis sites (Perio); Peri-
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Figure 4: GCF/PICF TNF-a levels comparing group A (Probiotic-test) versus 
Group B (Placebo-control).  Statistically significant difference in Day-90 compared to 
Day-0 in periodontitis and peri-implantitis sites in probiotic group.  Periodontally healthy 
sites (H); Periodontitis sites (P), Peri-implantitis sites (I); Probiotic group (A), Placebo 
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Figure 5: GCF/PICF MMP-9 levels between group A (probiotic-test) versus group B 
(placebo-control) among H (healthy), P (Periodontitis) and I (peri-implantitis) sites.  

























































































Figure 6: GCF/PICF RANKL levels between group A (probiotic-test) versus group 
B  (placebo-control) among H (healthy), P (Periodontitis) and I (peri-implantitis) 

































































































Figure 7:  GCF-PICF IL-1β levels between group A (probiotic-test) versus group B 
(placebo-control) among H (healthy), P (Periodontitis) and I (peri-implantitis) sites.  







































































































  Baseline 90d 
Placebo 
90d Probio Baseline 90d 
Placebo 
90d Probio 
Red Porphyromonas gingivalis 11.9 0.7 47.8 
 
261.3 0.8 176.6 
 
282.0625 6                             
445.1 
   Tannerella_forsythia 33.6 45.1 16.3 
 
113.5 161.0 71.0 
 
84.90625 83.5 46.0 
  Treponema_denticola 24.6 105.1 17.8   186.1 63.5 327.0   257.2813 155.7        150.6 
Orange Prevotella_intermedia 111.8 691.4 4.6 
 
22.33 1.8 789.1 
 
316.469 165.4 690.7 
 
Fusobacterium_nucleatum 690.7 20.1 58.1 
 
123.4 17.0 97.8 
 
70.8125 626.4 78.5 
 
Parvimonas_micra 51.2 58.5 28.1 
 
88.2 71.2 62.0 
 
189.1563 79.2 64.0 
 
Prevotella_nigrescens 226.7 425.1 124.5 
 
167.5 450.8 114.3 
 
248.6875 304.7 392.5 
 
Campylobacter_gracilis 250.6 247.4 169.0 
 
330.1 284.1 132.8 
 
140.6563 147.4 252.5 
  Eubacterium_nodatum 0.1 0 0.6   0.8 0 1.5   23.6875 8.0 40.5 
Green Eikenella_corrodens 150.9 46.4 61.6 
 
41.4 64.7 34.3 
 
37.9375 49.1 15.5 
 
Capnocytophaga granulosa 253.5 208.8 545.0 
 
219.8 202.2 214.6 
 
225.625 149.6 355.0 
  Campylobacter  concisus 11.6 36.7 10.5   3.8 3.2 45.5   3.59375 6.0 *54.5 
Yellow Streptococcus_sanguinis 1133.0 362.1 556.3 
 
763.0 885.7 170.8 
 
380.3125 279.5 212.9 
 
Streptococcus_intermedius 167.8 99.7 220.0 
 
147.7 96.0 12.8 
 
103.0938 10.8 9.42 
  Actinomyces species 3 0.7 2.830   4.8 8.7 9.3   13.71875 9.8 *186.2 
Purple Actinomyces graevenitzii 0.3 0.1 0 
 
0.1 0.2 0 
 
0.21875 0.1 *45.4 
  Veillonella parvula 938.8 1904.1 516.0   821.1 1055.2 1006.3   1303 1974.7 999.6 
             
Figure 8: Bacteria from the Socransky’s Complex Detected in Healthy (H), 
Periodontitis and Peri-implantitis sites in terms of colony-forming units (CFU).  
Statistically significant difference compared to baseline with p-value <0.05 are seen in 






































































Figure 9: Red complex bacteria units at baseline.  Statistically significant difference 
compared to healthy sites were marked in asterisks.  Periodontally healthy sites (H); 
Periodontitis sites (P); Peri-implantitis sites (PI); Porphyromonas Gingivalis species (Pg); 














































































Figure 10: Orange Complex Bacteria Units at Baseline Statistically significant 
difference compared to healthy sites marked with asterisks.  Peridontally healthy sites 
(H); Periodontitis sites (P); Peri-implantitis sites (PI); Prevotella intermedia species (Pi); 
Fusobacterium nucleatum (Fn); Parvimonas micra (Pm); Prevotella nigrescens (Pn); 





























































Figure 11: Green Complex Bacteria Units at Baseline. Periodontally healthy sites (H); 
Periodontitis sites (P); Peri-implantitis sites (PI); Eikenella corrodens species (Ec); 










































































Figure 12: Yellow Complex Bacteria Units at Baseline.  Statistically significant 
difference compared to healthy sites marked with asterisk.  Periodontally healthy sites 
(H); Periodontitis sites (P); Peri-implantitis sites (PI); Streptococcus sanquinis species 







































































Figure 13: Purple Complex Bacteria Units at Baseline.  Periodontally healthy sites 
(H); Periodontitis sites (P); Peri-implantitis sites (PI);  Actinomyces speciesv (Ac);  
















































































Figure 14: Red Complex Bacteria (Compared Baseline with Placebo and Probiotic 
groups at 90 days) for healthy, periodontitis and peri-implantitis sites.  
Porphyromonas gingivalis species (Pg); Tannerella forsythia species (Tf); Treponema 

































































Figure 15: Orange Complex Bacteria (Compared Baseline with Placebo and 
Probiotic groups at 90 days) for healthy, periodontitis and peri-implantitis sites.  
Statistically significant difference compared to baseline marked with an asterisk.  
Prevotella intermedia species (Pi); Fusobacterium nucleatum species (Fn); Parvimonas 
micra species (Pm); Prevotella nigrescens (Pn);  
Cg: Campylobacter gracilis  En: Eubacterium nodatum 
















































Figure 16: Green Complex Bacteria (Compared Baseline with Placebo and Probiotic 
groups at 90 days) for healthy, periodontitis and peri-implantitis sites.  Statistically 
significant differences compared to baseline are marked with asterisks.  Eikenella 























































Figure 17:  Yellow Complex Bacteria (Compared Baseline with Placebo and 
Probiotic groups at 90 days) for healthy, periodontitis and peri-implantitis sites.  No 
statistically significant differences were found among the placebo and probiotic groups.  































































Figure 18:  Purple Complex Bacteria (Compared Baseline with Placebo and 
Probitic groups at 90 days).  Statistically significant difference compared to baseline are 
marked with asterisks.  Actinomyces species(Actino); Actinomyces Odontolyticus (Ao); 
























































NOVA SOUTHEASTERN UNIVERSITY  
Health Professions Division – College of Dental Medicine  
General Informed Consent Form 
NSU Consent to be in a Research Study Entitled  
NSU IRB APPROVED: Approved: December 14, 2017 Expired: December 13, 
2018 IRB#: 2018-26-NSU  
Probiotic Supplements as Adjunct Therapy to Peri-Implantitis Lesions: A 
Double-Blind Randomized Controlled Trial  
Who is doing this research study?  
College: Nova Southeastern University Department of Periodontics Principal 
Investigator: Po Ning Polly Huang D.M.D.  
Faculty Advisor/Dissertation Chair: Saynur Vardar-Sengul D.D.S. Ph.D Co-
Investigator(s): Toshihisa Kawai 
Site Information: 
Funding: This study is funded by NSU grant  
What is this study about?  
You are invited to be in this research study. This study will evaluate the 
effectiveness of a probiotic on bone loss (peri-implantitis) after receiving a dental 
deep cleaning. The probiotics pill (Hyperbiotics-PRODENTAL) has been shown 
to bring good bacteria to the gums and decrease inflammation of the gums. This 
deep cleaning around the implants have been used for many years as part of the 
non-surgical procedure to treat peri-implantitis and is not considered new or 
experimental.  
Why are you asking me to be in this research study?  
We are inviting you to participate because you are a patient at the Nova 
Southeastern University College of Dental Medicine, and currently, you have at 
least one implant with bone loss around it that we called “peri-implantitis”. It is an 
inflammatory process around an implant where both the gums and the bone are 
affected and if not treated, you can eventually lose the implant(s).  
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To qualify for this study, you need to be: 
¬ At least 18 or older 
¬ Willing and able to give informed consent.  
In addition, you cannot have any of the following criteria listed below:  
• ¬  Uncontrolled medical conditions  
• ¬  Pregnant or lactating females  
• ¬  Use of antibiotics for the last 3 months.  
• ¬  Subjects treated for = 2 weeks with any medication known to affect soft 
tissue conditions (cyclosporine, phenytoin, Coumadin, etc.)  
• ¬  Patients taking bisphosphonate medication  
• ¬  Patients diagnosed with aggressive periodontitis  
• ¬  Patients taking immunosuppressive medications (steroids, biologics (like 
Humira, Enbrel) etc) or with a diagnosis of immunodeficiency.  
•  Patients who usually require antibiotic prophylaxis for a dental procedure 
(prosthetic heart valves, prior history of infectious endocarditis, congenital heart 
defects etc)  
What will I be doing if I agree to be in this research study?  
You will be required to attend a total of 5 appointments at different time periods 
at NSU Periodontics Dental Clinic over the course of 90 days. You will be asked 
to come back for several appointments after your cleaning for us to take some x-
rays of your implants and do some clinical measurements around the implants. 
The measurements done are the same kind of measurements that your hygienist 
regularly do to check the status of gums. We will use a paper point to collect 
bacteria sample around your affected implants. This procedure is non- invasive 
and is something that hygienists or dentists can do regularly to see what kind of 
bacteria are in your gums. This study will be completed in 90 days.  
Research Study Procedures - as a participant, this is what you will be 
doing:  
The following is a summary of what you can expect:  
Visit 1: Data collection (will take approximately 60 minutes) 
You will be asked to read and sign an Informed Consent form and will be given a 
copy. Your medical and dental history will be obtained, reviewed and kept in 
each study file stored in a secured cabinet. You will receive an oral exam to 
evaluate the general condition of your gums and especially the ones around your 
affected implant. Dr. Huang would remove some plaque from certain sites of the 
mouth with an instrument that is used to clean teeth (sterile curette). The 
collected plaque will be used as microbiological sample in this study. Moreover, 
we will use paper points to collect the fluid around the gums of your implant. It is 
a non-invasive procedure and is pain-free to measure the amount of 
inflammation of your gums. In addition, x-rays will be taken to evaluate the peri-
implantitis lesion(s).  
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Visit 2: Non-Surgical Therapy (Deep Cleaning) & Start taking tablets: (will 
take approximately 60 minutes) 
You will be asked to come back to the NSU PG Periodontics clinic for non-
surgical therapy (deep cleaning) on teeth with deep pockets and also around the 
implant(s). Dr. Huang or Dr. Vardar will show you appropriate home care 
techniques for optimal home care before you leave. Before leaving the 
appointment, you will be randomly assigned to a group. One group will take the 
probiotics pill and another group will take the placebo pill. The pills will be given 
to you in a bottle and you will be instructed to take 2 pills per day (one in morning 
and one at night). You will be asked to take the pills for 90 days.  
Visit 3: 7 days after last visit (will take approximately 60 minutes) 
You will report back to NSU PG Periodontics clinic. You will have a exam to 
evaluate the general condition of your gums and especially the ones around your 
affected implant. Some measurements will be taken with an instrument (probe) to 
assess the lesion(s) clinically. You will be reminded to continue to take the 
tablets given to you at your first (baseline) appointment as directed (two tablets 
per day) and home care techniques will be reviewed by Dr. Huang or Dr. Vardar.  
Visit 3: 30 days after visit 2 (will take approximately 60 minutes) 
You will report back to NSU PG Periodontics clinic. You will have a periodontal 
exam to evaluate the general condition of your gums and especially the ones 
around your affected implant. Some measurements will be taken with an 
instrument (probe) to assess the lesion(s) clinically. You will be reminded to 
continue to take the tablets given to you at your first (baseline) appointment as 
directed (two tablets per day) and home care techniques will be reviewed by Dr. 
Huang or Dr. Vardar.  
Visit 4: 60 days after visit 2 (will take approximately 60 minutes) 
You will report back to NSU PG Periodontics clinic. You will have a periodontal 
exam to evaluate the general condition of your gums and especially the ones 
around your affected implant. Some measurements will be taken with an 
instrument (probe) to assess the lesion(s) clinically. You will be reminded to 
continue to take the tablets given to you at your first (baseline) appointment as 
directed (two tablets per day) and home care techniques will be reviewed by Dr. 
Huang or Dr. Vardar.  
Visit 5: 90 days after baseline (final appointment) (will take approximately 60 
minutes) 
You will report back to NSU PG Periodontics clinic. You will have a periodontal 
exam to evaluate the general condition of your gums and especially the ones 
around your affected implant. Some measurements will be taken with an 
instrument (probe) to assess the lesion(s) clinically. Microbiological sampling will 
be collected. Moreover, the fluid around your implants will be collected with paper 
points. In addition, digital radiograph (xrays) will be taken to evaluate the peri-
implantitis lesion(s).  
Note: *Throughout the appointments, we may take some pictures using the Nikon 
SLR camera. Your face will NOT be photographed.  
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*The probiotics tablets are made in the USA in a facility that is Good 
Manufacturing Practice (GMP) certified. Contents of 1 tablet include: Zinc 2mg 
and Proprietary Probiotics Blend of 3 billion CFU (S. salivarius K 12, S .Salivarius 
M 18, L. reuteri, L. paracasei). It is also lactose free, vegetarian, non-GMO, yeast 
free, no lactose, no soy, no iron, no gluten, no wheat, no nuts, no preservatives.  
 
Could I be removed from the study early by the research team?  
Yes, you may be removed early from the research team. These reasons may be (but 
not limited to):  
• -  If you no longer meet the criteria to participate  
• -  If you fail to show up to scheduled appointments  
• -  If you fail to follow the study directions  
Are there possible risks and discomforts to me?  
This research study involves minimal risk to you. To the best of our knowledge, 
the things you will be doing have no more risk of harm than you would have in 
everyday life. 
This study is completely NON SURGICAL. This means no surgeries are involved. 
Thus, the risks are minimal. Some mild discomfort may be felt during the deep 
cleaning but the discomfort is the same as a regular cleaning with the hygienist. If 
you have more sensitive gums, we may numb you so you feel more comfortable. 
Minimal to none discomfort may be felt after the procedure for most people. In 
fact, the discomfort, if any, will not require any pain medications. If you have any 
pain post-procedure, please follow your dentist’s instructions for the post-
procedure management of pain. 
. 
The National Center for Complementary and Integrative Health stated “in healthy 
people, probiotics usually have only minor side effects, if any.” and “ in people 
who are generally healthy, probiotics have a good safety record. Side effects, if 
they occur at all, usually consist only of mild digestive symptoms such as gas”.  
If you feel slightly “gassy” in the beginning, that is completely normal as 
probiotics may increase some gas but most people will not feel any different. The 
gassy feeling should subside in less than a week if it is felt.  
What other treatment options are there to being in this research study?  
There are other options available to you. Your other choices may include: 1) get 
treatment or care without being in a study 
2) getting no treatment  
What if a research-related injury occurs?  
The researchers have taken steps to minimize the known or expected risks. 
However, you may still have problems or get side effects, even though the 
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researchers are careful to avoid them. In the event of a research-related injury or 
if you have a bad reaction, please contact Principal Investigator right away. See 
the contact section at the end of this form for phone numbers and more 
information.  
Nova Southeastern University does not have a program to pay you if you are hurt 
or have other bad results from being in this study. However, medical care at 
Nova Southeastern University is open to you as it is to all sick or injured people. 
If you have health insurance, the costs for any treatment or hospital care you 
receive as result of a study-related injury will be billed to your health insurer. Any 
costs that are not paid for by your health insurer will be billed to you. If you do not 
have health insurance, you will be billed for the costs of any treatment or hospital 
care you receive because of a study-related injury. If you sign this form, you do 
not give up your right to seek additional compensation if you are harmed 
because of participation in this study.  
What happens if I do not want to be in this research study?  
You have the right to leave this research study at any time or refuse to be in it. If 
you decide to leave or you do not want to be in the study anymore, you will not 
get any penalty or lose any services you have a right to get. If you choose to stop 
being in the study before it is over, any information about you that was collected 
before the date you leave the study will be kept in the research records for 36 
months from the end of the study and may be used as a part of the research.  
Are there risks related to withdrawing from the study early?  
If you decide to stop being in the study before it is over, please talk to the 
principal investigator about why you don’t want to be in the study any more.  
There is no risk to you if you do not complete the final withdrawal procedures and 
you can choose not to participate in them. However, note that not seeking any 
treatment for peri- implantitis lesions, you may be at risk for the lesion to 
progress and if lesion becomes more advanced, you may be at risk for losing the 
dental implant.  
What if there is new information learned during the study that may affect 
my decision to remain in the study? 
If significant new information relating to the study becomes available, which may 
relate to whether you want to remain in this study, this information will be given to 
you by the investigators. You may be asked to sign a new Informed Consent 
Form, if the information is given to you after you have joined the study.  
Are there any benefits for taking part in this research study?  
There are no direct benefits for participating in this study.  
Will I be paid or be given compensation for being in the study?  
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You will not be given any payments or compensation for being in this research 
study. 
The benefit of you being in this research study is that your treatment such as 
deep cleaning around the peri-implantitis lesions, microbiological sampling, 
digital radiographs and tablets given to you will be free of charge.  
Will it cost me anything?  
There are no costs to you for being in this research study.  
Will clinically relevant research results be shared with me?  
The study investigators do not plan to share research results with people in the 
study.  
How will you keep my information private?  
Information we learn about you in this research study will be handled in a 
confidential manner, within the limits of the law and will be limited to people who 
have a need to review this information. Organizations that may review and copy 
your information include the Institutional Review Board and other representatives 
of this institution. If we publish the results of the study in a scientific journal or 
book, we will not identify you. All confidential data will be kept securely All data 
will be kept for 36 months and destroyed after that time by deleting all encrypted 
information on the hard drive and by burning all the paper records.  
Will my biological specimens be used in future research studies?  
There is a possibility that the data collected from you may be shared with other 
investigators in the future. If that is the case, the data will not contain information 
that can identify you. You will not be contacted or asked to provide consent for 
the use of this data and/or specimens.  
Whom can I contact if I have questions, concerns, comments, or 
complaints?  
If you have questions now, feel free to ask us. If you have more questions about 
the research, your research rights, or have a research-related injury, please 
contact:  
Primary contact: 
Po- Ning Polly Huang D.M.D. can be reached at 412-387-8585  
If primary is not available, contact: 
Saynur Vardar-Sengul D.D.S., PhD can be reached at 954-262-1909  
Research Participants Rights  
For questions/concerns regarding your research rights, please contact:  
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Institutional Review Board 
Nova Southeastern University 
(954) 262-5369 / Toll Free: 1-866-499-0790 IRB@nova.edu  
You may also visit the NSU IRB website at www.nova.edu/irb/information-for-
research- participants for further information regarding your rights as a 
research participant.  
All space below was intentionally left blank.  
 
Voluntary Participation - You are not required to participate in this study. In the 
event you do participate, you may leave this research study at any time. If you 
leave this research study before it is completed, there will be no penalty to you, 
and you will not lose any benefits to which you are entitled.  
If you agree to participate in this research study, sign this section. You will be 
given a signed copy of this form to keep. You do not waive any of your legal 
rights by signing this form.  
SIGN THIS FORM ONLY IF THE STATEMENTS LISTED BELOW ARE TRUE:  
• You have read the above information.  
•		Your questions have been answered to your satisfaction about the research.  
 
Adult Signature Section  
I have voluntarily decided to take part in this research study.  
 
Printed Name of Participant  
Printed Name of Person Obtaining Consent and Authorization  
Signature of Participant Date  
Signature of Person Obtaining Consent & Date Authorization  
 
Initials: _________ Date: ___________ 
3200	South	University	Drive	•	Fort	Lauderdale,	Florida	33328-2018	(954)	262-1301	•	800-672-1802 
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